Current Psychiatry Reports

, Volume 1, Issue 2, pp 172–178 | Cite as

Current concepts in pharmacotherapy of substance abuse

  • P. Christopher H. Gottschalk
  • Leslie K. Jacobsen
  • Thomas R. Kosten
Article

Abstract

The cost to society of alcohol, tobacco, and illicit drug dependence is enormous. Although the importance of treatment for substance abuse to public health is increasingly acknowledged, pharmacotherapy is generally underutilized. However, the selection of medications for clinical testing is increasingly guided by the rapidly evolving science of addictive drugs and behavior. The benefit of medication for smoking cessation is firmly established, particularly for nicotine replacement and antidepressant therapy. Naltrexone is an important addition to the pharmacopoeia, and acamprosate may soon be approved as well. Although no new medications are approved for cocaine and amphetamine abuse, a variety of candidate treatments have shown promise in ongoing studies. Opiate substitution therapy is highly effective for rehabilitation of heroin addiction, and several alternative forms will soon be available; alternative forms of opiate detoxification have also received attention. Overall, there is increasing recognition that physicians have an obligation to identify and treat all forms of substance dependence, although knowledge of the efficacy of the available treatments is steadily increasing.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Cinciripini PM, Hecht SS, Henningfield JE, et al.: Tobacco addiction: implications for treatment and cancer prevention. J Natl Cancer Inst 1997, 89:1852–1867.PubMedCrossRefGoogle Scholar
  2. 2.
    Amaro HP: An Expensive Policy: The Impact of Inadequate Funding for Substance Abuse Treatment [editorial]. American Journal of Public Health 1999, 89:657–659.PubMedGoogle Scholar
  3. 3.
    Nestler EJ: Molecular mechanisms of opiate and cocaine addiction. Curr Opin Neurobiol 1997, 7:713–719.PubMedCrossRefGoogle Scholar
  4. 4.
    O’Brien CP: A range of research-based pharmacotherapies for addiction [see comments]. Science 1997, 278:66–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Gorelick DA: The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol 1998, 42:995–997.PubMedCrossRefGoogle Scholar
  6. 6.
    Sinclair JD: New treatment options for substance abuse from a public health viewpoint. Ann Med 1998, 30:406–411.PubMedGoogle Scholar
  7. 7.
    Kranzler H, Rounsaville B: Dual Diagnosis: Substance Abuse and Comorbid Medical and Psychiatric Disorders. New York: Marcel Dekker; 1998.Google Scholar
  8. 8.
    Silagy C, Mant D, Fowler G, et al.: Nicotine replacement therapy for smoking cessation (Cochrane Review), vol. 2. Oxford: Update Software; 1999.Google Scholar
  9. 9.
    Hughes JR, Goldstein MG, Hurt RD, et al.: Recent advances in the pharmacotherapy of smoking. JAMA 1999, 281:72–76. A remarkably detailed, evidence-based review of the available therapies, how to use them, and how to advise patients in their use.PubMedCrossRefGoogle Scholar
  10. 10.
    Raw M, McNeill A, West R: Smoking cessation guidelines for health professionals. A guide to effective smoking cessation interventions for the health care system. Health Education Authority. Thorax 1998, 53:S1-S19. Detailed guidelines for implementing effective interventions at many levels of a health care system.CrossRefGoogle Scholar
  11. 11.
    Britton J, Knox A: Helping people to stop smoking: the new smoking cessation guidelines. Thorax 1999, 54:1–2.PubMedGoogle Scholar
  12. 12.
    Fiore M, Baker T: Smoking cessation treatment and the good doctor club. Am J Public Health 1995, 85:161–163.PubMedGoogle Scholar
  13. 13.
    Smoking Cessation Clinical Practice Guideline: The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. JAMA 1996, 275:1270–1280.Google Scholar
  14. 14.
    Hughes J, Fiester S, Goldstein M, et al.: American Psychiatric Association practice guideline for the treatment of patients with nicotine dependence. Am J Psychiatry 1996, 153(suppl):S1-S31.Google Scholar
  15. 15.
    Gariti P, Alterman AI, Barber W, et al.: Cotinine replacement levels for a 21 mg/day transdermal nicotine patch in an outpatient treatment setting. Drug Alcohol Depend 1999, 54:111–116.PubMedCrossRefGoogle Scholar
  16. 16.
    Jorenby DE, Leischow SJ, Nides MA, et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999, 340:685–691.PubMedCrossRefGoogle Scholar
  17. 17.
    Hayford KE, Patten CA, Rummans TA, et al.: Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999, 174:173–178.PubMedGoogle Scholar
  18. 18.
    Picciotto MR: Common aspects of the action of nicotine and other drugs of abuse. Drug Alcohol Depend 1998, 51:165–172. An outstanding, concise review that integrates basic and behavioral research to provide an understanding of available therapies and the opportunities for new research.PubMedCrossRefGoogle Scholar
  19. 19.
    Krishnan-Sarin S, Rosen MI, O’Malley SS: Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Arch Gen Psychiatry 1999, 56:663–668.PubMedCrossRefGoogle Scholar
  20. 20.
    Garbutt JC, West SL, Carey TS, et al.: Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999, 281:1318–1325. Reviews all available evidence with ratings and discussion of their relevance.PubMedCrossRefGoogle Scholar
  21. 21.
    Gatch MB, Lal H: Pharmacological treatment of alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 1998, 22:917–944.PubMedCrossRefGoogle Scholar
  22. 22.
    Lejoyeux M, Solomon J, Ades J: Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol 1998, 33 563–575.PubMedGoogle Scholar
  23. 23.
    Litten RZ, Allen JP: Advances in development of medications for alcoholism treatment. Psychopharmacology (Berl) 1998, 139:20–33.CrossRefGoogle Scholar
  24. 24.
    Swift RM: Drug therapy for alcohol dependence. N Engl J Med 1999, 340:1482–1490.PubMedCrossRefGoogle Scholar
  25. 25.
    Tinsley JA, Finlayson RE, Morse RM: Developments in the treatment of alcoholism. Mayo Clin Proc 1998, 73:857–863.PubMedGoogle Scholar
  26. 26.
    Tsai G, Coyle JT: The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med 1998, 49:173–184.PubMedCrossRefGoogle Scholar
  27. 27.
    Pelc I, Verbanck P, Le Bon O, et al.: Efficacy and safety of acamprosate in the treatment of detoxified alcoholdependent patients. A 90-day placebo-controlled dosefinding study. Br J Psychiatry 1997, 171:73–77.PubMedCrossRefGoogle Scholar
  28. 28.
    Hersh D, Van Kirk JR, Kranzler HR: Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology (Berl) 1998, 139:44–52.CrossRefGoogle Scholar
  29. 29.
    Oslin DW, Pettinati HM, Volpicelli JR, et al.: The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J Subst Abuse Treat 1999, 16:163–167.PubMedCrossRefGoogle Scholar
  30. 30.
    Mendelson JH, Mello NK: Management of cocaine abuse and dependence. N Engl J Med 1996, 334:965–972.PubMedCrossRefGoogle Scholar
  31. 31.
    Haney M, Collins ED, Ward AS, et al.: Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine selfadministration in humans. Psychopharmacology (Berl) 1999, 143:102–110.CrossRefGoogle Scholar
  32. 32.
    Sofuoglu M, Pentel PR, Bliss RL, et al.: Effects of phenytoin on cocaine self-administration in humans. Drug Alcohol Depend 1999, 53:273–275.PubMedCrossRefGoogle Scholar
  33. 33.
    McCance-Katz EF, Kosten TR, Jatlow P: Disulfiram effects on acute cocaine administration. Drug Alcohol Depend 1998, 52:27–39.PubMedCrossRefGoogle Scholar
  34. 34.
    Renshaw PF, Daniels S, Lundahl LH, et al.: Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report. Psychopharmacology (Berl) 1999, 142:132–138.CrossRefGoogle Scholar
  35. 35.
    Bartzokis G, Beckson M, Newton T, et al.: Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. Neuropsychopharmacology 1999, 20:582–590.PubMedCrossRefGoogle Scholar
  36. 36.
    Landry DW: Immunotherapy for cocaine addiction. Sci Am 1997, 276:42–45.PubMedCrossRefGoogle Scholar
  37. 37.
    Gorelick DA: Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend 1997, 48:159–165.PubMedCrossRefGoogle Scholar
  38. 38.
    Carroll FI, Howell LL, Kuhar MJ: Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 1999, 42:2721–2736. An exhaustive review of all compounds tested and their mechanism of action.PubMedCrossRefGoogle Scholar
  39. 39.
    Gatley SJ, Volkow ND, Gifford AN, et al.: Model for estimating dopamine transporter occupancy and subsequent increases in synaptic dopamine using positron emission tomography and carbon-11-labeled cocaine. Biochem Pharmacol 1997, 53:43–52.PubMedCrossRefGoogle Scholar
  40. 40.
    Volkow ND, Wang GJ, Fowler JS, et al.: Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 1999, 65:L7-L12.CrossRefGoogle Scholar
  41. 41.
    Logan J, Volkow ND, Fowler JS, et al.: Concentration and occupancy of dopamine transporters in cocaine abusers with 11C cocaine and PET. Synapse 1997, 27:347–356.PubMedCrossRefGoogle Scholar
  42. 42.
    Volkow ND, Wang GJ, Fowler JS, et al.: Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high". J Pharmacol Exp Ther 1999, 288:14–20.PubMedGoogle Scholar
  43. 43.
    Volkow ND, Wang GJ, Fowler JS, et al.: Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998, 155:1325–1331.PubMedGoogle Scholar
  44. 44.
    Gawin F, Riordan C, Kleber H: Methylphenidate treatment of cocaine abusers without attention deficit disorder: a negative report. Am J Drug Alcohol Abuse 1985, 11:193–197.PubMedGoogle Scholar
  45. 45.
    Levin FR, Evans SM, McDowell DM, Kleber HD: Methylphenidate treatment for cocaine abusers with adult. Journal of Clinical Psychiatry 1998, 59:300–305.PubMedGoogle Scholar
  46. 46.
    Anonymous: Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998, 280:1936–1943. A clear statement in support of opiate substitution therapy from the NIH.Google Scholar
  47. 47.
    Olivet AH, Farren C, Kosten TR: Effect of LAAM dose on opiate use in opioid-dependent patients. A pilot study. Am J Addict 1998, 7:272–282.Google Scholar
  48. 48.
    Avants SK, Margolin A, DePhilippis D, Kosten TR: A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients. Preliminary findings. J Subst Abuse Treat 1998, 15:261–265.PubMedCrossRefGoogle Scholar
  49. 49.
    Drucker E, Vlahov D: Controlled clinical evaluation of diacetyl morphine for treatment of intractable opiate dependence. Lancet 1999, 353:1543–1544.PubMedCrossRefGoogle Scholar
  50. 50.
    Bammer G, Dobler-Mikol A, Fleming PM, et al.: The Heroin Prescribing Debate: Integrating Science and Politics. Science 1999, 284:1277–1278.PubMedCrossRefGoogle Scholar
  51. 51.
    Kienbaum P, Thurauf N, Michel MC, et al.: Profound increase in epinephrine concentration in plasma and cardiovascular stimulation after mu-opioid receptor blockade in opioidaddicted patients during barbiturate-induced anesthesia for acute detoxification [see comments]. Anesthesiology 1998, 88:1154–1161.PubMedCrossRefGoogle Scholar
  52. 52.
    Gevirtz C, Subhedar DV, Choi CS: Rapid opioid detoxification [letter; comment]. JAMA 1998, 279:1871, discussion 1872.CrossRefGoogle Scholar
  53. 53.
    Pfab R, Hirtl C, Zilker T: Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure. J Toxicol Clin Toxicol 1999, 37:43–50.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • P. Christopher H. Gottschalk
    • 1
  • Leslie K. Jacobsen
    • 1
  • Thomas R. Kosten
    • 1
  1. 1.Veteran’s Affairs Medical CenterWest HavenUSA

Personalised recommendations